Albert A Hagege
Overview
Explore the profile of Albert A Hagege including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maron M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Arad M, et al.
J Am Coll Cardiol
. 2024 Oct;
84(19):1821-1831.
PMID: 39352339
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has...
2.
Coats C, Masri A, Nassif M, Barriales-Villa R, Arad M, Cardim N, et al.
J Am Heart Assoc
. 2024 Jul;
13(15):e035993.
PMID: 39056349
Background: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM...
3.
Maron M, Masri A, Nassif M, Barriales-Villa R, Arad M, Cardim N, et al.
N Engl J Med
. 2024 May;
390(20):1849-1861.
PMID: 38739079
Background: One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract...
4.
Coats C, Maron M, Abraham T, Olivotto I, Lee M, Arad M, et al.
JACC Heart Fail
. 2023 Nov;
12(1):199-215.
PMID: 38032573
Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients...
5.
Reaney M, Allen V, Sehnert A, Fang L, Hagege A, Naidu S, et al.
Pharmacoecon Open
. 2022 Jun;
6(4):563-574.
PMID: 35653062
Background: Currently, there is no patient-reported outcome (PRO) instrument specifically designed to evaluate hypertrophic cardiomyopathy (HCM). Objective: We present the development and psychometric validation of a novel PRO measure, the...
6.
Yu M, Kyryachenko S, Debette S, Amouyel P, Schott J, Le Tourneau T, et al.
Circ Genom Precis Med
. 2021 Aug;
14(5):e003148.
PMID: 34461747
Background: Mitral valve prolapse (MVP) is a common cardiac valve disease, which affects 1 in 40 in the general population. Previous genome-wide association study has identified 6 risk loci for...
7.
Messas E, Ijsselmuiden A, Goudot G, Vlieger S, Zarka S, Puymirat E, et al.
Circulation
. 2021 Jan;
143(9):968-970.
PMID: 33486971
No abstract available.
8.
Ledieu N, Larnier L, Auffret V, Marie C, Fargeau D, Donal E, et al.
Europace
. 2019 Oct;
22(1):139-148.
PMID: 31603495
Aims: To identify independent electrocardiogram (ECG) predictors of long-term clinical outcome based on standardized analysis of the surface ECG in a large multicentre cohort of patients with sarcomeric hypertrophic cardiomyopathy...
9.
Yu M, Georges A, Tucker N, Kyryachenko S, Toomer K, Schott J, et al.
Circ Genom Precis Med
. 2019 May;
12(5):e002497.
PMID: 31112420
Background Mitral valve prolapse (MVP) is a common heart valve disease, the most frequent indication for valve repair or replacement. MVP is characterized by excess extracellular matrix secretion and cellular...
10.
Schwammenthal E, Hagege A, Levine R
J Am Soc Echocardiogr
. 2019 Mar;
32(3):341-343.
PMID: 30827370
No abstract available.